Ocata Therapeutics Provides Corporate Update For The Second Quarter Of 2015
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today provided a corporate update for the second quarter of 2015.
“During the quarter, we made significant progress across multiple aspects of our business, most notably towards the initiation of a Phase 2 study in dry AMD and a pivotal study in SMD,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.
“During the quarter, we made significant progress across multiple aspects of our business, most notably towards the initiation of a Phase 2 study in dry AMD and a pivotal study in SMD,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.